Chetachi Blessing Okwuanaso

Mrs. Chetachi Blessing Okwuanaso


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2025 in Viruses
Verified
Journal Article
Open access
PDF file
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
Ikemefuna UzochukwuIkemefuna Uzochukwu
Ikemefuna Uzochukwu
FEFortunatus Ezebuo
Fortunatus Ezebuo
IEInnocentMary IfedibaluChukwu Ejiofor
InnocentMary IfedibaluChukwu Ejiofor
MAMercy Adeola Adebola
Mercy Adeola Adebola
Juan De La TorreJuan De La Torre
Juan De La Torre
Lassa fever (LF), a viral hemorrhagic fever disease with a case fatality rate that can be over 20% among hospitalized LF patients, is endemic to many West African countries. Currently, no vaccines or therapies are specifically licensed to prevent or treat LF, hence the significance of developing therapeutics against the mammarenavirus Lassa virus (LASV), the causative agent of LF. We used in silico docking approaches to investigate the binding affinities of 2015 existing drugs to LASV proteins known to play critical roles in the formation and activity of the virus ribonucleoprotein complex (vRNP) responsible for directing replication and transcription of the viral genome. Validation of docking protocols were achieved with reference inhibitors of the respective targets. Our in silico docking screen identified five drugs (dexamethasone, tadalafil, mefloquine, ergocalciferol, and flunarizine) with strong predicted binding affinity to LASV proteins involved in the formation of the vRNP. We used cell-based functional assays to evaluate the antiviral activity of the five selected drugs. We found that flunarizine, a calcium-entry blocker, inhibited the vRNP activity of LASV and LCMV and virus surface glycoprotein fusion activity required for mammarenavirus cell entry. Consistently with these findings, flunarizine significantly reduced peak titers of LCMV in a multi-step growth kinetics assay in human A549 cells. Flunarizine is being used in several countries worldwide to treat vertigo and migraine, supporting the interest in exploring its repurposing as a candidate drug to treat LASV infections.

30 December 2024 in African Journal of Clinical and Experimental Microbiology
Verified
Journal Article
Open access
PDF file
COChetachi Blessing Okwuanaso
Chetachi Blessing Okwuanaso
NON. F. Onyemelukwe
N. F. Onyemelukwe
COC. A. Ofodile
C. A. Ofodile
Background: Food-borne illnesses are a major cause of morbidity and death worldwide, and food safety and hygiene play a critical role in maintaining and improving consumer health. One significant factor in the prevalence of food-related illnesses associated with unclean food is the way food vendors handle their inventory. As a result, this study evaluated the level of food handlers' adherence to cleanliness and safety standards, as well as the variables affecting them in the city of Nnewi. This study evaluated degree of safety and hygiene practices, as well as the factors influencing them, among food handlers in the Nnewi metropolis.Methodology: A cross-sectional study of 428 consenting food handlers was carried out in Nnewi metropolis utilizing quantitative data gathering methodologies and non-probability method of sampling. A well-structured and pre-tested questionnaire was interviewer-administered to collect information on sociodemographic characteristics, food safety and hygiene practices, knowledge of food safety, and observational checklists that covered cleaning, sanitation and personal hygiene. Evaluation of safety and hygiene practices was done using a four-point scale of responses from participants, with scores equal and above the 50th percentile classified as good practices, while scores less than the 50th percentile as poor practices Data were analyzed using Minitab version 21.2 and SPSS version 27.0. P value < 0.05 was considered significant.Results: The mean age of the 428 food handlers who responded, was 33.89±10.29 years, with female preponderance (83.4%, n=357). A total of 217 (50.7%) respondents were adjudged to be of good practices of food safety while 211 (49.3%) were of bad practices. Statistical analysis showed that food safety and cleanliness habits were significantly associated with age, marital status, and gender (p0.05).Conclusion: The data indicate that certain demographic factors significantly impact food safety practices, pointing to potential areas for intervention, such as enhancing training and monitoring, particularly among younger, married, and less-educated food handlers, and ensuring the presence of running water in the vending premises. Food safety and cleanliness standards need to be raised because maintaining and enhancing health depends on food's wholesomeness and maximum safety.

30 December 2024 in African Journal of Clinical and Experimental Microbiology
Verified
Journal Article
Open access
PDF file
COChetachi Blessing Okwuanaso
Chetachi Blessing Okwuanaso
NON. F. Onyemelukwe
N. F. Onyemelukwe
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
Background: There is a public health concern about carriage of Enterobacterales among food workers and their potential role for transmission of food-borne illnesses. Food contamination by Enterobacterales could happen at any point of the production, processing, distribution, and preparation processes. This challenge is especially severe in developing countries like Nigeria. The objective of this study is to determine the prevalence and pattern of carriage of Enterobacterales by food handlers in Nnewi metropolis, southeast Nigeria.Methodology: This was a cross-sectional study that employed a non-probability sampling technique to recruit 178 food handlers who gave their consent and were available at the sampling area during the time of the study. Stool, urine, nasal and hand swab samples were collected from 115, 116, 120 and 173 food handlers respectively for microbiological analysis using conventional culture isolation and biochemical identification by Analytical Profile Index (API) 20E (bioMérieux). The antimicrobial susceptibility testing of the isolates was carried out on the identified isolates by the disk diffusion method. Descriptive statistics were carried out on the data.Results: Forty-four (25.4%) of the hand swab samples from 173 food handlers, 39 (32.5%) of the nasal swabs from 120 food handlers, 67 (58.3%) of the stool samples from 115 food handlers, and 29 (25.0%) of the urine samples from 116 food handlers, were positive for Enterobacterales isolates. The frequency of Enterobacterales isolation was significantly higher from stool samples compared to other samples (x2=40.032; p<0.0001), indicating a higher carriage rate in the gastrointestinal tracts of the food handlers. Across all the samples, a total of 179 Enterobacterales were isolated from the 101 (56.7%) positive food handlers. The frequency of isolation in descending order is Escherichia coli 23.2% (n=41), Klebsiella spp 18.1% (n=32), Enterobacter spp 15.3% (n=27), Citrobacter spp 10.7% (n=19), Raoultella spp 7.3% (n=13), Serratia spp 5.6% (n=10), Salmonella spp 3.9% (n=7), Kluyvera spp 3.9% (n=7), Shigella spp 2.8% (n=5), Proteus spp 2.8% (n=5), Cronobacter spp 1.7% (n=3), Erwinia spp 1.1% (n=2), Pantoea spp 1.1% (n=2), Hafnia spp 1.1% (n=2), and Yersinia spp 1.1% (n=2). The Enterobacterales isolates were resistant to cefotaxime (83.0%), amoxicillin-clavulanic acid (79.1%), cefuroxime (76.8%), cefixime (75.1%), imipenem-cilastatin (74.6%), ceftazidime-avibactam (73.3%), ceftriaxone-sulbactam (71.2%) and levofloxacin (70.5%).Conclusion: Food handlers in this study had a high carriage rate of resistant Enterobacterales pathogens, which can be transmitted to unsuspecting consumers, through the food processing and handling chains.

25 November 2025 in bioRxiv
Verified
Preprint
Open access
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
BIBeatrice Cubitt IMM-6
Beatrice Cubitt IMM-6
NONgozi Onyemelukwe
Ngozi Onyemelukwe
COChetachi Blessing Okwuanaso
Chetachi Blessing Okwuanaso
HWHaydar Jawad Kathim Witwit
Haydar Jawad Kathim Witwit
JTJuan C. de la Torre
Juan C. de la Torre
Mammarenaviruses (MaAv) cause persistent infection in their natural rodent hosts across the world and via zoonotic events can cause severe disease in humans. Thus, the MaAv Lassa virus (LASV) in Western Africa and Junin virus (JUNV) in the Argentinean Pampas cause hemorrhagic fever diseases with significant case fatality rates in their endemic regions. In addition, the globally distributed MaAv lymphocytic choriomeningitis virus (LCMV) is an underrecognized human pathogen of clinical significance capable of causing devastating infections in neonates and immunocompromised individuals. Despite their impact on human health, there are currently no FDA-approved vaccines or specific antiviral treatments for MaAv infections. Existing anti-MaAv therapies are limited to the off-label use of ribavirin whose efficacy remains controversial, hence, the significance of developing novel therapeutics to combat human pathogenic MaAv. We employed a high-throughput cell-based infection assay to screen the Pandemic Response Box, a collection of 400 diverse compounds with established antimicrobial activity, for MaAv inhibitors. We identified Ro-24-7429, an antagonist of the HIV-1 Tat protein and RUNX Family Transcription Factor 1 inhibitor; WO 2006118607 A2, a dihydroorotate dehydrogenase inhibitor; and verdinexor, a novel selective inhibitor of nuclear export (SINE) targeting the CRM1/XPO1, as potent anti-MaAv compounds. Consistent with their distinct validated targets, verdinexor and WO 2006118607 A2 exhibited a very strong synergistic antiviral activity when used in combination therapy. Our findings pave the way for the development of verdinexor as a potent host-directed antiviral against MaAv, which could be integrated into the development of combination therapy with direct-or host-acting antivirals to combat human pathogenic MaAv.

14 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
Ikemefuna UzochukwuIkemefuna Uzochukwu
Ikemefuna Uzochukwu
FEFortunatus Ezebuo
Fortunatus Ezebuo
IEInnocentMary IfedibaluChukwu Ejiofor
InnocentMary IfedibaluChukwu Ejiofor
MAMercy Adeola Adebola
Mercy Adeola Adebola
Juan De La TorreJuan De La Torre
Juan De La Torre
Lassa fever (LF), a viral hemorrhagic fever disease with a case fatality rate that can be over 20% among hospitalized LF patients, is endemic to many West African countries. Currently, no vaccines or therapies are specifically licensed to prevent or treat LF. Hence, the significance of developing therapeutics against the mammarenavirus Lassa virus (LASV), the causative agent of LF. We used in silico docking approaches to investigate the binding affinities of 2015 existing drugs to LASV proteins known to play critical roles in the formation and activity of the virus ribonucleoprotein complex (vRNP) responsible for directing replication and transcription of the viral genome. Validation of docking protocols were achieved with reference inhibitors of the respective targets. Our in silico docking screen identified five drugs (dexamethasone, tadalafil, mefloquine, ergocalciferol, and flunarizine) with strong predicted binding affinity to LASV proteins involved in the formation of the vRNP. We used cell-based functional assays to evaluate the antiviral activity of the five selected drugs. We found that flunarizine, a calcium-entry blocker, inhibited the vRNP activity of LASV and LCMV, and virus surface glycoprotein fusion activity required for mammarenavirus cell entry. Consistent with these findings, flunarizine significantly reduced peak titers of LCMV in a multi-step growth kinetics assay in human A549 cells. Flunarizine is being used in several countries worldwide to treat vertigo and migraine, supporting the interest in exploring its repurposing as a candidate drug to treat LASV infections.

12 January 2026 in Viruses
Verified
Journal Article
Open access
PDF file
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
BIBeatrice Cubitt IMM-6
Beatrice Cubitt IMM-6
NONgozi Onyemelukwe
Ngozi Onyemelukwe
COChetachi Blessing Okwuanaso
Chetachi Blessing Okwuanaso
HWHaydar Jawad Kathim Witwit
Haydar Jawad Kathim Witwit
Juan De La TorreJuan De La Torre
Juan De La Torre
Mammarenaviruses (MaAv) cause persistent infection in their natural rodent hosts across the world and, via zoonotic events, can cause severe disease in humans. Thus, the MaAv Lassa virus (LASV) in Western Africa and the Junin virus (JUNV) in the Argentinean Pampas cause hemorrhagic fever diseases with significant case fatality rates in their endemic regions. In addition, the globally distributed MaAv lymphocytic choriomeningitis virus (LCMV) is an underrecognized human pathogen of clinical significance capable of causing devastating infections in neonates and immunocompromised individuals. Despite their impact on human health, there are currently no FDA-approved vaccines or specific antiviral treatments for MaAv infections. Existing anti-MaAv therapies are limited to the off-label use of ribavirin, whose efficacy remains controversial; hence, the development of novel therapeutics to combat human pathogenic MaAv is vital. We employed a high-throughput cell-based infection assay to screen the Pandemic Response Box, a collection of 400 diverse compounds with established antimicrobial activity, for MaAv inhibitors. We identified Ro-24-7429, an antagonist of the HIV-1 Tat protein and RUNX family transcription factor 1 inhibitor; WO 2006118607 A2, a dihydroorotate dehydrogenase inhibitor; and verdinexor, a novel selective inhibitor of nuclear export (SINE) targeting the XPO1/CRM1, as potent anti-MaAv compounds. Consistent with their distinct validated targets, verdinexor and WO 2006118607 A2 exhibited very strong synergistic antiviral activity when used in combination therapy. Our findings pave the way for the development of verdinexor as a potent host-directed antiviral against MaAv, which could be integrated into the development of combination therapy with direct- or host-acting antivirals to combat human pathogenic MaAv.